• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

Progression of COVID-19 reduced after high-titer convalescent plasma administration

byRicha SharmaandHarsh Shah
February 18, 2021
in Infectious Disease, Public Health, Pulmonology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Majority of the patients that received high-titer convalescent plasma within 72 hours of mild symptom onset were shown to reduce the coronavirus disease 2019 (COVID-19) severe illness progression.

2. The IgG titer distribution between the treatment group and placebo group revealed a significant difference.

Evidence Rating Level: 1 (Excellent)

Study Rundown: The number of deaths, as a result of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been extremely high among the elderly population. However, studies displaying the use of plasma therapy are limited. This randomized control trial examined the outcome of early high-titer convalescent plasma therapy in older adults with mild COVID-19 symptoms. Patients were randomly assigned to either receive convalescent plasma or a placebo. Patients that received the high-titer plasma therapy displayed a reduction in COVID-19 disease progression. Additionally, the greater number of patients that received the placebo suffered from life-threatening respiratory disease and/or a critical systemic illness. The study was limited by a small number of study participants resulting in a low power value. Moreover, the study data cannot be generalized to all SARS-CoV-2 infected patients, instead can only be applied to elderly patients. Nonetheless, this study’s results are significant, and its findings highlight that high-titer convalescent plasma can reduce the severity of the coronavirus disease.

Click to read the study in NEJM

Relevant Reading: Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19

In-Depth [randomized controlled trial]: This study enrolled 160 patients between June 4, 2020, and October 25, 2020, across hospitals in Argentina. This study enrolled participants who were 75 years of age or older, regardless of any existing comorbidities and patients between the ages of 65 and 74 with at least one or more comorbidities. In order to be eligible, patients had to have at least one sign or symptom of COVID-19. Patients with severe respiratory disease at the time of enrollment were excluded from the study. Patients were randomized in a 1:1 ratio to receive high-titer convalescent plasma or placebo, respectively. Severe respiratory disease was the primary study endpoint which was defined as a high respiratory rate of 30 breaths per minute or more, low oxygen saturation of 92% or less while the patient was on room air or both. Overall, 16% of the patients in the treatment group developed a severe respiratory disease compared to 31% patients in the placebo group (relative risk, 0.52; 95% confidence interval [CI], 0.29 to 0.94; P = 0.03). There was a 48% relative risk reduction as a result of administering convalescent plasma. Only 5% of the convalescent group developed life-threatening respiratory disease whereas 12% of the placebo group manifested such a form. Overall, the study showed that early administration of convalescent plasma can be beneficial to elderly patients and can reduce COVID-19 disease progression.

RELATED REPORTS

Vaccination boosted immunity acquired from previous SARS-CoV-2 infection

Single-dose Ad26.COV2.S vaccine provides moderate protection against Covid-19 related outcomes

BNT162b2 safe and efficacious in children 5 to 11 years of age

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: convalescent plasmaSARS-CoV-2
Previous Post

Maternal chronic conditions increase risk of cerebral palsy among offspring

Next Post

#VisualAbstract: Enfortumab vedotin prolongs survival in previously treated advanced urothelial carcinoma

RelatedReports

Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children
Chronic Disease

Vaccination boosted immunity acquired from previous SARS-CoV-2 infection

May 13, 2022
Novel coronavirus identified from patients with pneumonia in Wuhan, China
Chronic Disease

Single-dose Ad26.COV2.S vaccine provides moderate protection against Covid-19 related outcomes

May 13, 2022
Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children
Chronic Disease

BNT162b2 safe and efficacious in children 5 to 11 years of age

May 13, 2022
Masks for personal protection for SARS-CoV-2 infection
Chronic Disease

Adding mask recommendation did not significantly reduce the SARS-CoV-2 infection rate

May 13, 2022
Next Post
#VisualAbstract: Nivolumab plus ipilimumab increases overall survival in patients with malignant pleural mesothelioma

#VisualAbstract: Enfortumab vedotin prolongs survival in previously treated advanced urothelial carcinoma

#VisualAbstract Bortezomib, cyclophosphamide, and dexamethasone demonstrated a modest median event-free survival in transplant ineligible patients with multiple myeloma

#VisualAbstract Bortezomib, cyclophosphamide, and dexamethasone demonstrated a modest median event-free survival in transplant ineligible patients with multiple myeloma

#VisualAbstract: Addition of palbociclib to adjuvant endocrine therapy does not improve survival in patients with HR⁺, HER2- breast cancer

#VisualAbstract: Skin biopsy rates have disproportionately increased compared to cancer treatments between 1993-2016

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Long-acting cabotegravir significantly decreases incidence of HIV compared to daily oral tenofovir
  • Oral methylprednisolone may reduce risk of progressive renal failure in patients with IgA nephropathy: TESTING Trial
  • #VisualAbstract: Adjuvant capecitabine improves long-term survival in early breast cancer
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.